 |
|
A Randomized Trial of an N-methyl-D-aspartate Antagonist in Treatment-Resistant Major Depression
Carlos A. Zarate, Jr, MD;
Jaskaran B. Singh, MD;
Paul J. Carlson, MD;
Nancy E. Brutsche, MSN;
Rezvan Ameli, PhD;
David A. Luckenbaugh, MA;
Dennis S. Charney, MD;
Husseini K. Manji, MD, FRCPC
Arch Gen Psychiatry. 2006;63:856-864.
Context Existing therapies for major depression have a lag of onset of action of several weeks, resulting in considerable morbidity. Exploring pharmacological strategies that have rapid onset of antidepressant effects within a few days and that are sustained would have an enormous impact on patient care. Converging lines of evidence suggest the role of the glutamatergic system in the pathophysiology and treatment of mood disorders.
Objective To determine whether a rapid antidepressant effect can be achieved with an antagonist at the N-methyl-D-aspartate receptor in subjects with major depression.
Design A randomized, placebo-controlled, double-blind crossover study from November 2004 to September 2005.
Setting Mood Disorders Research Unit at the National Institute of Mental Health.
Patients Eighteen subjects with DSM-IV major depression (treatment resistant).
Interventions After a 2-week drug-free period, subjects were given an intravenous infusion of either ketamine hydrochloride (0.5 mg/kg) or placebo on 2 test days, a week apart. Subjects were rated at baseline and at 40, 80, 110, and 230 minutes and 1, 2, 3, and 7 days postinfusion.
Main Outcome Measure Changes in scores on the primary efficacy measure, the 21-item Hamilton Depression Rating Scale.
Results Subjects receiving ketamine showed significant improvement in depression compared with subjects receiving placebo within 110 minutes after injection, which remained significant throughout the following week. The effect size for the drug difference was very large (d = 1.46 [95% confidence interval, 0.91-2.01]) after 24 hours and moderate to large (d = 0.68 [95% confidence interval, 0.13-1.23]) after 1 week. Of the 17 subjects treated with ketamine, 71% met response and 29% met remission criteria the day following ketamine infusion. Thirty-five percent of subjects maintained response for at least 1 week.
Conclusions Robust and rapid antidepressant effects resulted from a single intravenous dose of an N-methyl-D-aspartate antagonist; onset occurred within 2 hours postinfusion and continued to remain significant for 1 week.
Trial Registration clinicaltrials.gov Identifier: NCT00088699.
Author Affiliations: Mood and Anxiety Disorders Program, National Institute of Mental Health, National Institutes of Health, and Department of Health and Human Services, Bethesda, Md.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
RELATED LETTERS
Searching for Rational Anti–N-methyl-D-aspartate Treatment for Depression
Guochuan E. Tsai
Arch Gen Psychiatry. 2007;64(9):1099-1100.
EXTRACT
| FULL TEXT
Searching for Rational Anti–N-methyl-D-aspartate Treatment for Depression—Reply
Carlos A. Zarate, Jr, Dennis S. Charney, and Husseini K. Manji
Arch Gen Psychiatry. 2007;64(9):1100-1101.
EXTRACT
| FULL TEXT
Tailoring Treatment to Parental Values: A Comment on TADS—Reply
John S. March and for the TADS Team
Arch Gen Psychiatry. 2008;65(6):723-724.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
The STAR*D Trial: Revealing the Need for Better Treatments
Insel and Wang
Psychiatr. Serv. 2009;60:1466-1467.
ABSTRACT
| FULL TEXT
The Role of the Tripartite Glutamatergic Synapse in the Pathophysiology and Therapeutics of Mood Disorders
Machado-Vieira et al.
Neuroscientist 2009;15:525-539.
ABSTRACT
Is there a neuroendocrinological rationale for testosterone as a therapeutic option in depression?
Ebinger et al.
J Psychopharmacol 2009;23:841-853.
ABSTRACT
Altered Prefrontal Glutamate-Glutamine-{gamma}-Aminobutyric Acid Levels and Relation to Low Cognitive Performance and Depressive Symptoms in Type 1 Diabetes Mellitus
Lyoo et al.
Arch Gen Psychiatry 2009;66:878-887.
ABSTRACT
| FULL TEXT
Neurobiological mechanisms in major depressive disorder
aan het Rot et al.
CMAJ 2009;180:305-313.
FULL TEXT
HCN1 Channel Subunits Are a Molecular Substrate for Hypnotic Actions of Ketamine
Chen et al.
J. Neurosci. 2009;29:600-609.
ABSTRACT
| FULL TEXT
AMPA receptor subunit 1 (GluR-A) knockout mice model the glutamate hypothesis of depression
Chourbaji et al.
FASEB J. 2008;22:3129-3134.
ABSTRACT
| FULL TEXT
Tailoring Treatment to Parental Values: A Comment on TADS--Reply
March and for the TADS Team
Arch Gen Psychiatry 2008;65:723-724.
FULL TEXT
Major Depressive Disorder
Belmaker and Agam
NEJM 2008;358:55-68.
FULL TEXT
Recent Findings in the Pathophysiology of Depression
Nemeroff
Focus 2008;6:3-14.
FULL TEXT
Chronic N-methyl-D-aspartate administration increases the turnover of arachidonic acid within brain phospholipids of the unanesthetized rat
Lee et al.
J. Lipid Res. 2008;49:162-168.
ABSTRACT
| FULL TEXT
Anesthetic Pharmacology: Reflections of a Section Editor
Bovill
Anesth. Analg. 2007;105:1186-1190.
FULL TEXT
Searching for Rational Anti N-methyl-D-aspartate Treatment for Depression
Tsai
Arch Gen Psychiatry 2007;64:1099-1100.
FULL TEXT
Role of N-Methyl-D-aspartate Receptors in Antidepressant-Like Effects of {sigma}1 Receptor Agonist 1-(3,4-Dimethoxyphenethyl)-4-(3-phenylpropyl)piperazine Dihydrochloride (SA-4503) in Olfactory Bulbectomized Rats
Wang et al.
J. Pharmacol. Exp. Ther. 2007;322:1305-1314.
ABSTRACT
| FULL TEXT
Modafinil Add-On in the Treatment of Bipolar Depression
Belmaker
Am. J. Psychiatry 2007;164:1143-1145.
FULL TEXT
Association of GRIK4 With Outcome of Antidepressant Treatment in the STAR*D Cohort
Paddock et al.
Am. J. Psychiatry 2007;164:1181-1188.
ABSTRACT
| FULL TEXT
|
